The FDA has cleared their once-weekly Factor VIII replacement therapy Altuviiio (efanesoctocog alfa) for adults and children with haemophilia A, giving Sanofi and Sobi a successor to well ...

Sanofi expects to generate annual sales of over €10 billion by 2030, driven by recently launched products like Altuviiio (for hemophilia A), Sarclisa (for multiple myeloma) and Tzield (for ...